GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration

Nature Neuroscience

Volumn 18, Issue 4, 2015, Pages 521-530

  Winkler, Ethan A ^a,b   Nishida, Yoichiro ^c,d   Sagare, Abhay P ^a   Rege, Sanket V ^a   Bell, Robert D ^c   Perlmutter, David ^c   Sengillo, Jesse D ^a,c   Hillman, Sara ^c   Kong, Pan ^a   Nelson, Amy R ^a   Sullivan, John S ^a   Zhao, Zhen ^a   Meiselman, Herbert J ^a   Wenby, Rosalinda B ^a   Soto, Jamie ^e   Abel, E Dale ^e   Makshanoff, Jacob ^a   Zuniga, Edward ^a   De Vivo, Darryl C ^f   Zlokovic, Berislav V ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e UNIVERSITY OF IOWA   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; GLUCOSE TRANSPORTER 1; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; ENDOTHELIUM; GLUCOSE TRANSPORT; MOUSE; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; ANIMAL; BRAIN CIRCULATION; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-BRAIN BARRIER; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GLUCOSE TRANSPORTER TYPE 1; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

EID: 84925594369     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn.3966     Document Type: Article

References (63)

1. Zlokovic, B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201 (2008).
2. Zlokovic, B.V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 12, 723-738 (2011).
3. Simpson, I.A., Carruthers, A. & Vannucci, S.J. Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J. Cereb. Blood Flow Metab. 27, 1766-1791 (2007).
4. Deng, D. et al. Crystal structure of the human glucose transporter GLUT1. Nature 510, 121-125 (2014).
5. Allen, A. & Messier, C. Plastic changes in the astrocyte GLUT1 glucose transporter and beta-tubulin microtubule protein following voluntary exercise in mice. Behav. Brain Res. 240, 95-102 (2013).
6. Choeiri, C., Staines, W., Miki, T., Seino, S. & Messier, C. Glucose transporter plasticity during memory processing. Neuroscience 130, 591-600 (2005).
7. Zeller, K., Rahner-Welsch, S. & Kuschinsky, W. Distribution of Glut1 glucose transporters in different brain structures compared to glucose utilization and capillary density of adult rat brains. J. Cereb. Blood Flow Metab. 17, 204-209 (1997).
8. Pearson, T.S., Akman, C., Hinton, V.J., Engelstad, K. & De Vivo, D.C. Phenotypic spectrum of glucose transporter type 1 defciency syndrome (Glut1 DS). Curr. Neurol. Neurosci. Rep. 13, 342 (2013).
9. Wang, D. et al. A mouse model for Glut-1 haploinsuffciency. Hum. Mol. Genet. 15, 1169-1179 (2006).
10. Ullner, P.M. et al. Murine Glut-1 transporter haploinsuffciency: postnatal deceleration of brain weight and reactive astrocytosis. Neurobiol. Dis. 36, 60-69 (2009).
11. Zheng, P.-P. et al. Glut1/SLC2A1 is crucial for the development of the blood-brain barrier in vivo. Ann. Neurol. 68, 835-844 (2010).
12. Nguyen, L.N. et al. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature 509, 503-506 (2014).
13. Ben-Zvi, A. et al. Mfsd2a is critical for the formation and function of the blood-brain barrier. Nature 509, 507-511 (2014).
14. Zhao, Z. & Zlokovic, B.V. Blood-brain barrier: a dual life of MFSD2A? Neuron 82, 728-730 (2014).
15. Landau, S.M. et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 72, 578-586 (2012).
16. Winkler, E.A., Sagare, A.P. & Zlokovic, B.V. The pericyte: a forgotten cell type with important implications for Alzheimer's disease? Brain Pathol. 24, 371-386 (2014).
17. Ossenkoppele, R. et al. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology 80, 359-365 (2013).
18. Protas, H.D. et al. Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol. 70, 320-325 (2013).
19. Mosconi, L. et al. Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiol. Aging 34, 22-34 (2013).
20. Landau, S.M. et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75, 230-238 (2010).
21. Mosconi, L. et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verifed Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 36, 811-822 (2009).
22. Mosconi, L. et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J. Nucl. Med. 47, 1778-1786 (2006).
23. Niwa, K., Kazama, K., Younkin, S.G., Carlson, G.A. & Iadecola, C. Alterations in cerebral blood fow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis. 9, 61-68 (2002).
24. Jagust, W.J. et al. Diminished glucose transport in Alzheimer's disease: dynamic PET studies. J. Cereb. Blood Flow Metab. 11, 323-330 (1991).
25. Piert, M., Koeppe, R.A., Giordani, B., Berent, S. & Kuhl, D.E. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. J. Nucl. Med. 37, 201-208 (1996).
26. Simpson, I.A., Chundu, K.R., Davies-Hill, T., Honer, W.G. & Davies, P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann. Neurol. 35, 546-551 (1994).
27. Mooradian, A.D., Chung, H.C. & Shah, G.N. GLUT-1 expression in the cerebra of patients with Alzheimer's disease. Neurobiol. Aging 18, 469-474 (1997).
28. Kalaria, R.N. & Harik, S.I. Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease. J. Neurochem. 53, 1083-1088 (1989).
29. Horwood, N. & Davies, D.C. Immunolabelling of hippocampal microvessel glucose transporter protein is reduced in Alzheimer's disease. Virchows Arch. 425, 69-72 (1994).
30. Hsiao, K. et al. Correlative memory defcits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99-102 (1996).
31. Young, C.D. et al. Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS ONE 6, e23205 (2011).
32. Deane, R. et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9, 907-913 (2003).
33. Paris, D. et al. Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci. Lett. 366, 80-85 (2004).
34. Paris, D. et al. Inhibition of angiogenesis by Aβ peptides. Angiogenesis 7, 75-85 (2004).
35. Abdul Muneer, P.M., Alikunju, S., Szlachetka, A.M., Murrin, L.C. & Haorah, J. Impairment of brain endothelial glucose transporter by methamphetamine causes blood-brain barrier dysfunction. Mol. Neurodegener. 6, 23 (2011).
36. Iadecola, C. et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci. 2, 157-161 (1999).
37. Niwa, K. et al. Aβ1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc. Natl. Acad. Sci. USA 97, 9735-9740 (2000).
38. Paul, J., Strickland, S. & Melchor, J.P. Fibrin deposition accelerates neurovascular damage and neuroinfammation in mouse models of Alzheimer's disease. J. Exp. Med. 204, 1999-2008 (2007).
39. Deane, R. et al. LRP/amyloid beta-peptide interaction mediates differential brain effux of Aβ isoforms. Neuron 43, 333-344 (2004).
40. Obermoeller-McCormick, L.M. et al. Dissection of receptor folding and ligand-binding property with functional minireceptors of LDL receptor-related protein. J. Cell Sci. 114, 899-908 (2001).
41. Uchida, Y. et al. A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice. Fluids Barriers CNS 10, 21 (2013).
42. Bell, R.D. et al. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat. Cell Biol. 11, 143-153 (2009).
43. Llorente-Cortés, V., Costales, P., Bernués, J., Camino-Lopez, S. & Badimon, L. Sterol regulatory element-binding protein-2 negatively regulates low density lipoprotein receptor-related protein transcription. J. Mol. Biol. 359, 950-960 (2006).
44. Bell, R.D. et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512-516 (2012).
45. Irizarry, M.C., McNamara, M., Fedorchak, K., Hsiao, K. & Hyman, B.T. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 56, 965-973 (1997).
46. Benarroch, E.E. Brain glucose transporters: implications for neurologic disease. Neurology 82, 1374-1379 (2014).
47. Vannucci, S.J. Developmental expression of GLUT1 and GLUT3 glucose transporters in rat brain. J. Neurochem. 62, 240-246 (1994).
48. Bolaños, J.P., Delgado-Esteban, M., Herrero-Mendez, A., Fernandez-Fernandez, S. & Almeida, A. Regulation of glycolysis and pentose-phosphate pathway by nitric oxide: impact on neuronal survival. Biochim. Biophys. Acta 1777, 789-793 (2008).
49. Sagare, A.P. et al. Pericyte loss infuences Alzheimer-like neurodegeneration in mice. Nat. Commun. 4, 2932 (2013).
50. Seidner, G. et al. GLUT-1 defciency syndrome caused by haploinsuffciency of the blood-brain barrier hexose carrier. Nat. Genet. 18, 188-191 (1998).
51. Bell, R.D. et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 68, 409-427 (2010).
52. 14C]iodoantipyrine injection and fnal arterial heart blood sampling. J. Cereb. Blood Flow Metab. 20, 10-14 (2000).
53. Chow, N. et al. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood fow dysregulation in Alzheimer's phenotype. Proc. Natl. Acad. Sci. USA 104, 823-828 (2007).
54. Wu, Z. et al. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat. Med. 11, 959-965 (2005).
55. Zlokovic, B.V., Mackic, J.B., Wang, L., McComb, J.G. & McDonough, A. Differential expression of Na, K-ATPase alpha and beta subunit isoforms at the blood-brain barrier and the choroid plexus. J. Biol. Chem. 268, 8019-8025 (1993).
56. Menon, P. et al. Impaired spine formation and learning in GPCR kinase 2 interacting protein-1 (GIT1) knockout mice. Brain Res. 1317, 218-226 (2010).
57. LaRue, B. et al. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice. J. Neurosci. Methods 138, 233-242 (2004).
58. 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106, 1489-1499 (2000).
59. Fowler, S.C. et al. A force-plate actometer for quantitating rodent behaviors: illustrative data on locomotion, rotation, spatial patterning, stereotypies, and tremor. J. Neurosci. Methods 107, 107-124 (2001).
60. Deacon, R.M.J. Assessing nest building in mice. Nat. Protoc. 1, 1117-1119 (2006).
61. Schildge, S., Bohrer, C., Beck, K. & Schachtrup, C. Isolation and culture of mouse cortical astrocytes. J. Vis. Exp. doi:10.3791/50079 (19 January 2013).
62. Baskurt, O.K. et al. Comparison of three commercially available ektacytometers with different shearing geometries. Biorheology 46, 251-264 (2009).
63. Agarwal, N. et al. Familial polycythemia caused by a novel mutation in the beta globin gene: essential role of P50 in evaluation of familial polycythemia. Int. J. Med. Sci. 4, 232-236 (2007).